GermanyGermany

Cancer immunotherapeutics specialist immatics raises EUR54m

23.09.2010

Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.

GermanyGermany

01.07.2010

Penzberg (Germany) - Diagnostics and IT giants Roche and IBM are joining forces to bring down the cost of DNA sequencing to a few hundred euros. On Thursday, the companies announced that they will develop a nanopore-based DNA...

GermanyGermany

22.06.2010

Berlin – The German Bioethics Council has proposed to establish new rules to secure sensitive personal data stored in biobanks of human specimens. The new rules proposed to be applied internationally foresee the creation of a...

GermanyGermany

17.06.2010

Ingelheim – Just one week after Boehringer Ingelheim GmbH announced Phase III results, which suggested its 5-HT and dopamine D receptor agonist flibanserin boosted sexual desire in women with hypoactive sexual desire disorder,...

GermanyGermany

16.06.2010

Hamburg/Melbourne – Researchers have discovered a new drug target that blocks the malaria parasite from entering human blood cells (PLoSPathog.Jun 3;6(6):e100094). Currently, there is no vaccine against the Plasmodium parasite...

GermanyGermany

15.06.2010

Martinsried/Bethesda – Micromets bifunctional monoclonal antibody drug blinatumomab (MT103) has met its study goals in two independent clinical trails. In a Phase I dose escalation study in 52 adult patients with relapsed...

GermanyGermany

03.06.2010

Tuebingen - German Immatics biotechnologies heaps up partners for it cancer vaccine IMA950. The biotechnology company from Tuebingen announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research...

GermanyGermany

01.06.2010

Martinsried – Researchers from the Max Planck Insitute for Biochemistry have presented a novel technique that enables them to map the entire pattern of N-glycosylation (linking a sugar to the amino acid asparagine) and the...

Displaying results 101 to 110 out of 454

< Previous 101-110 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/10/article/cancer-immunotherapeutics-specialist-immatics-raises-eur54-million.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events